Napier AI’s 2025/26 global AML Index, researched by Napier AI in partnership with Global Data, ranks 40 global markets based ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called ...

Time and again, seemingly successful bank mergers have been rocked by revelations of poor anti-money-laundering compliance. Assessing the AML risk of a potential merger partner is extremely tricky, ...

By combining proteasome inhibitors with a second drug that disables one of two backup survival pathways, the team was able to ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

To further explore the potential of synthetic triterpenoids as possible novel agents for the treatment of AML, we determined the effects of CDDO and CDDO-m on apoptosis induction in vitro, using ...

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...